Peptide Pedia
The reference library
Compound profiles, mechanisms and research summaries across every domain in the catalogue. Written to be looked something up in rather than browsed — each entry states what the published literature establishes, and stops there.
- Entries
- 12
- Domains
- 09
- Includes
- CAS · formula · mass
- Framing
- Research only
Compound entries
12 entries
NAD+
Nicotinamide adenine dinucleotide · Coenzyme I · NAD · NAD plus
Longevity · Extensively studied
Functions as an obligate electron acceptor in catabolic oxidation and as the substrate consumed by NAD-dependent enzymes. Published work examines how the balance between synthesis via the salvage pathway and consumption by PARPs, sirtuins and CD38 determines the free pool available for oxidative phosphorylation.
- CAS
- 53-84-9
- Mass
- ≈ 663.43 g/mol
- Presentation
- 500 mg / vial
99.17%COARetatrutide
Triple agonist · LY3437943 · Reta · GLP-1 triagonist
Weight Loss · Emerging
Characterised as engaging GIPR, GLP-1R and GCGR from one backbone. The glucagon arm is examined for hepatic effects on lipid handling and for its contribution to energy expenditure, which distinguishes the pharmacology from incretin-only agonists that act principally on insulin secretion and appetite pathways.
- CAS
- 2381089-83-2
- Mass
- ≈ 4731.40 g/mol
- Presentation
- 10 mg / vial
99.38%COATesamorelin
GRF(1-44) analogue · TH9507 · Tesamorelin acetate
Growth · Established
Described as binding the GHRH receptor on somatotrophs and raising intracellular cyclic AMP, increasing the amplitude of endogenous secretory pulses rather than imposing a continuous signal. The N-terminal modification is studied for the resistance to dipeptidyl peptidase-4 cleavage that extends the interval over which the analogue remains intact.
- CAS
- 218949-48-5
- Mass
- ≈ 5135.86 g/mol
- Presentation
- 10 mg / vial
No batchBPC-157 + TB-500
BPC-157 · TB-500 · Body Protection Compound-157 · Thymosin beta-4 fragment · Pentadecapeptide BPC 157 · Tβ4
Recovery · Extensively studied
BPC-157 is described in published models as upregulating vascular endothelial growth factor receptor 2 with downstream activity along the VEGFR2-Akt-eNOS axis, alongside modulation of the nitric oxide system and effects on focal adhesion kinase that underlie the fibroblast migration reported in tendon preparations. TB-500 is characterised as sequestering monomeric G-actin, shifting the polymerisation equilibrium and altering cytoskeletal turnover. The pairing is examined as angiogenic signalling and cytoskeletal mobilisation measured in one model.
- CAS
- 137525-51-0 / 77591-33-4
- Mass
- ≈ 1419.53 / 4963.44 g/mol
- Presentation
- 5 mg + 5 mg / vial
99.82%COACJC-1295 / Ipamorelin
CJC-1295 no-DAC with Ipamorelin · GHRH analogue blend · CJC-1295 · Ipamorelin
Growth · Established
CJC-1295 is characterised as engaging the GHRH receptor on somatotrophs, raising cyclic AMP and increasing the amplitude of secretory pulses. Ipamorelin is described as acting at GHS-R1a through a distinct Gq-coupled route, without the cortisol and prolactin cross-reactivity reported for earlier secretagogues. The two inputs are studied as additive rather than redundant.
- CAS
- 863288-34-0 / 170851-70-4
- Mass
- ≈ 3367.80 / 711.85 g/mol
- Presentation
- 5 mg + 5 mg / vial
99.33%COAMOTS-c
Mitochondrial ORF of the 12S rRNA type-c · MOTSc · Mitochondrial-derived peptide
Metabolism · Established
Described as inhibiting the folate cycle and accumulating AICAR, which in turn activates AMPK. Under metabolic stress the peptide is reported to translocate to the nucleus and associate with stress-response transcription factors, positioning it as a signal between the mitochondrial and nuclear genomes.
- CAS
- 1627580-64-6
- Mass
- ≈ 2174.62 g/mol
- Presentation
- 10 mg / vial
99.29%COAGHK-Cu
Copper tripeptide-1 · Glycyl-L-histidyl-L-lysine copper · GHK · Copper peptide
Longevity · Extensively studied
The tripeptide is described as a physiological copper carrier, exchanging Cu(II) with albumin at a defined affinity and delivering it to cells. Downstream literature reports modulation of several hundred genes in fibroblast models, with particular attention to the balance between matrix metalloproteinases and their tissue inhibitors.
- CAS
- 89030-95-5
- Mass
- ≈ 401.91 g/mol
- Presentation
- 50 mg / vial
99.68%COASemax
ACTH(4-10) analogue · N-acetyl semax · Semax acetate
Neuro · Established
Characterised as raising BDNF and NGF transcript levels in hippocampal and cortical preparations without the adrenocorticotropic activity of the parent fragment. Additional work examines effects on the dopaminergic and serotonergic systems and on markers of cerebral perfusion in ischaemia models.
- CAS
- 80714-61-0
- Mass
- ≈ 813.93 g/mol
- Presentation
- 10 mg / vial
99.66%COASelank
Tuftsin analogue · TP-7 · Selank acetate
Neuro · Emerging
The proline-glycine-proline extension is described as conferring resistance to peptidase cleavage, extending the window over which the tuftsin core is available. Published work examines inhibition of enkephalin-degrading enzymes and changes in GABAergic and serotonergic gene expression in hippocampal preparations.
- CAS
- 129954-34-3
- Mass
- ≈ 751.88 g/mol
- Presentation
- 10 mg / vial
99.74%COASNAP-8
Acetyl octapeptide-3 · Acetyl glutamyl heptapeptide-3 · Acetyl octapeptide-1
Regeneration · Emerging
Described as competing with SNAP-25 for a position in the SNARE complex, so that the assembly forms less efficiently. The literature examines the consequence for vesicle docking and catecholamine release in cell models, and the acetylation at the N-terminus is studied for the stability it confers on a short sequence.
- CAS
- 868844-74-0
- Mass
- ≈ 1025.06 g/mol
- Presentation
- 10 mg / vial
No batchMelanotan II
MT-2 · Melanotan 2 · MT2 · Melanocortin analogue
Performance · Established
Described as engaging melanocortin receptors with the conformational constraint of the cyclic lactam bridge holding the pharmacophore in an active orientation. Published work examines MC1R engagement in melanocyte preparations and MC3R and MC4R engagement in hypothalamic models, and treats the lack of subtype selectivity as the defining feature of the molecule.
- CAS
- 121062-08-6
- Mass
- ≈ 1024.18 g/mol
- Presentation
- 10 mg / vial
No batchBacteriostatic Water
Bacteriostatic water for injection · BAC water · Sterile water for injection · Diluent
Preparation · Established
The benzyl alcohol content is bacteriostatic rather than bactericidal: it inhibits microbial growth in the vial between entries. It is not an active compound and it has no pharmacology of its own in this context. Compatibility is the property that matters, and it is stated per compound on the certificate of analysis.
- CAS
- 7732-18-5 (water) / 100-51-6 (benzyl alcohol)
- Mass
- ≈ 18.02 g/mol (water)
- Presentation
- 10 mL / vial
No batch
Alphabetical index
The same entries, ordered by name rather than by domain, for when you already know what you are looking for.
Enquiries
Looking for something not listed?
The library reflects what is currently held to the EVOHN specification. If a compound is absent, the desk can say whether it can be sourced to the same standard.